Allied Corp. has successfully completed an 80kg export of THC-based medical cannabis to one of its GMP (Good Manufacturing Practices) manufacturing partners in Europe. The shipment has cleared customs. Through its partner, Allied will offer to the European market flower and derivatives manufactured with GMP certification – a key requirement for import into several countries, including Germany.
This comes at a time when the European medical cannabis market received a significant boost with the German Cannabis Decriminalization Act (Pillar 1) which came into effect on 1 April 2024. Under the Act, cannabis has been officially removed from Germany's Narcotics List which is expected to drastically improve patient access and support further adoption of medical cannabis. Patients will no longer require a narcotic prescription form, which experts say will simplify the process for doctors and streamline the medical cannabis supply chain. The legislation also allows adults to possess up to 25g for personal use and cultivate up to three plants for private consumption, while paving the way for wider recreational legalization.
"With this shipment and its established European channel partnerships, Allied is set to play a key role in rapidly expanding markets, including Germany," said Juba Hadid, VP of Global Sales. "This also solidifies the particular attractiveness of Allied's offering to international buyers: high quality at a low cost."
This shipment follows the recent 180kg purchase order, two international flower distribution agreements signed earlier this year and two successful shipments of THC-based medical cannabis to Australia in November 2023.
For more information:
Allied Corp
allied.health